[Intolerance to and/or drug interactions of anti-HIV and anti-HVC therapy]

Details

Serval ID
serval:BIB_C80C674F1D06
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Title
[Intolerance to and/or drug interactions of anti-HIV and anti-HVC therapy]
Journal
Med Mal Infect
Author(s)
Galperine T., Merle C., de Truchis P., Bernard L., Perronne C.
ISSN
0399-077X (Print)
ISSN-L
0399-077X
Publication state
Published
Issued date
03/2005
Volume
35
Number
3
Pages
135-40
Language
english
Notes
Galperine, T
Merle, C
de Truchis, P
Bernard, L
Perronne, C
fre
English Abstract
Review
France
2005/05/25
Med Mal Infect. 2005 Mar;35(3):135-40. doi: 10.1016/j.medmal.2004.11.004.
Abstract
Treating Hepatitis C among HIV patients under antiretroviral drug therapy requires a high degree of vigilance and continuous monitoring because of frequent problems with intolerance and/or drug interactions. Recent studies, including three therapeutic trials, on Ribavic, APRICOT, and ACTG A5671, have given some insights on following these patients up. The adverse effects are relatively similar in HCV-HIV-co-infected patients and patients infected by HCV only. Their frequency is, on the other hand, higher among HCV-HIV-Co-infected patients. The adverse-effects are consistent, in a non-exhaustive way, with pseudo influenza-like symptoms, fever, myalgia, cephalgia, with psychiatric disorders (irritability, depression, etc.); endocrine disorders (thyroid dysfunction, diabetes...); and with hematological anomalies especially anemia and leucopenia. But the percentage of lymphocyte T CD4 is not modified, therefore there is no risk of opportunistic infection. Pharmacokinetic interactions between antiretroviral drugs and treatment for HCV infection including ribavirin plus interferon alpha (IFN-alpha) or pegylated IFN are described. They are almost exclusively due to the combination of ribavirin and of nucleoside analogue reverse transcriptase inhibitors. One of the principal consequences is the emergence of mitochondrial toxicity defined by the occurrence of hyperlactatemia, or acute pancreatitis). Thus, some combinations should be avoided such as ddI+ribavirin and ddI+d4T+ribavirin. The d4T+ribavirin combination must also be used with caution.
Keywords
Antiviral Agents/*adverse effects/pharmacokinetics/*therapeutic use, Comorbidity, Drug Interactions, Drug Therapy, Combination, HIV Infections/*drug therapy, Hepatitis C/*drug therapy, Humans, Risk Factors
Pubmed
Create date
30/01/2023 12:16
Last modification date
31/01/2023 7:55
Usage data